What to Expect From Biogen's $2.3 Billion Shopping Spree
After selling its stake in a biosimilar joint venture with Samsung Biologics, Biogen (NASDAQ: BIIB) has reportedly now brought Goldman Sachs on board to identify potential acquisition targets. Brian Orelli: Biogen sold off its stake in its biosimilar joint venture that it has with Samsung Biologics.